TRAVERSE Trial Video Series: Prostate Safety Events

[madman]

Webinars

live.arealive.org

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

4 heavyweights in the field, Morgentaler, Traish, Khera and Zitzmann!




4:16-19:45 (Panel Discussion)

 

[madman]

Testosterone Therapy Today: Clinical Advances & Safety with Dr. Abraham Morgentaler

Dr. Morgentaler back in action! Listen closely, loved this one! Pros/Cons oral TU (51:24-57:12) *one of the things that the orals have transformed is the concept that you have to have a continually high level of testosterone to get the benefits and clearly that's not true and the...

www.excelmale.com

 

[madman]

Testosterone and Prostate Cancer - 2 Key Topics

Great webinar! Nelson's house is where it's at! 3:20-18:38 * Safety of TTh in men with treated or low-grade in-situ prostate cancer is unknown * Will never have a study large enough to know true impact of T on prostate cancer development/progression

www.excelmale.com

 

[madman]

The Shocking Truth Between Testosterone and Prostate Cancer

Another great interview from Dr. Bernie! * debunk the long-standing myth that testosterone fuels prostate cancer In this episode, Dr. Geo interviews Dr. Helen Bernie from Indiana University about Testosterone Replacement Therapy (TRT) post-prostate cancer diagnosis and treatment. They...

www.excelmale.com

 

[madman]

Prostate Risk and Monitoring During TRT

ABSTRACT Men with hypogonadism have reduced risk of prostate cancer mortality; whether testosterone treatment increases the risk of prostate safety events in men with hypogonadism remains controversial. Several studies including four larger randomized trials — the Testosterone Trials...

www.excelmale.com

What the TRAVERSE Trial did and did not show


At its core, the TRAVERSE Trial shows that TRT of middle-aged and older men with hypogonadism with a PSA <3.0 ng/mL, who had been screened carefully to exclude those at high risk of prostate cancer, is associated with low risk of high grade or any prostate cancer. Several caveats apply to this inference. First, because the numbers and incidence of high grade or any prostate cancer in the two groups were very low, these data should not be interpreted to mean that the incidence was similar in the two groups. Second, even though TRAVERSE is among the longest and the largest trials of TRT, with 14,304 person -23 years of follow-up and an average follow-up duration of 33 months, carcinogens typically take a long period of time to cause cancer. Long-term differences in risk of prostate cancer in men receiving testosterone or placebo are unknown. Third, in line with American Urological Association/Society of Urologic Oncology (AUA/SUO) guidelines, an elevated PSA was repeated in all men prior to consideration of further evaluation (49,50). Additionally, men were provided access to a standardized informational video about the potential benefits and risks of prostate biopsy to ensure shared decision-making regarding their desire for further evaluation. These steps likely reduced the number of persons undergoing prostate biopsy. Fourth, prostate imaging or genetic testing studies were not performed as part of the evaluation; it is possible that the availability of these additional diagnostic studies could have changed the decision to perform prostate biopsy. Finally, men at increased risk of prostate cancer were excluded from the trial; the trial's findings do not apply to men at high risk of prostate cancer.